Condition
Leukemia Relapse
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (1)
P 4 (2)
Trial Status
Recruiting2
Terminated1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07284433Phase 1Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT02618109Phase 4Terminated
Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia
NCT03793517Phase 2Recruiting
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
NCT03190733Phase 4Unknown
A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT
Showing all 4 trials